Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Technology evaluation: electroporation therapy, Genetronics Inc.

¹CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK. rosanne@icr.ac.uk

Current Opinion in Molecular Therapeutics

|March 16, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Determining cut-off scores for simulated tasks in Brazilian Air Force military personnel.

BMJ military health·2024

Same author

Antisense therapy for cancer.

IDrugs : the investigational drugs journal·2008

Same author

Molecular targets and cancer therapeutics: discovery, development & clinical validation--AACR-NCI-EORTC international conference.

IDrugs : the investigational drugs journal·2005

Same author

GTI-2040. Lorus Therapeutics.

Current opinion in investigational drugs (London, England : 2000)·2002

Same author

Technology evaluation: leukemia therapy, University of Pennsylvania.

Current opinion in molecular therapeutics·2001

Same author

Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.

Current opinion in molecular therapeutics·2001

Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011

Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010

Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010

Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010

Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010

Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010

See all related articles

Electroporation therapy uses electric pulses to enhance anticancer drug delivery directly into tumors, minimizing systemic toxicity. Clinical studies show promising results for various cancers, including head and neck, with minimal side effects.

Area of Science:

Biomedical Engineering
Oncology
Medical Devices

Background:

Systemic administration of cytotoxic drugs often leads to severe side effects.
Intracellular drug delivery is a key challenge in cancer chemotherapy.
Electroporation therapy offers a novel approach to targeted drug delivery.

Purpose of the Study:

To evaluate the efficacy and safety of electroporation therapy in cancer treatment.
To assess the potential of electroporation for enhanced intracellular accumulation of anticancer drugs.
To report clinical outcomes of electroporation therapy in patients with cutaneous and subcutaneous tumors.

Main Methods:

Development of the MedPulser device and needle array applicator for electroporation.
Combination of electric pulses with intratumoral injections of anticancer drugs (e.g., bleomycin).

Related Experiment Videos

Conducting preclinical and clinical studies, including Phase II trials for various cancers.

Main Results:

Electroporation therapy enables intracellular drug accumulation, bypassing systemic toxicity.
Objective responses observed in a Phase II study of head and neck cancer patients (1999).
Minimal side effects reported in clinical studies across multiple cancer types.

Conclusions:

Electroporation therapy is a promising approach for targeted cancer treatment.
The technique facilitates effective drug delivery with an improved safety profile.
Further clinical trials are warranted to establish its role in standard cancer care.